

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 80829

Title: Access to novel anti-diabetic agents in resource limited settings- a brief

commentary

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02459759 Position: Associate Editor Academic degree: MD

**Professional title:** Professor

Reviewer's Country/Territory: China

Author's Country/Territory: South Africa

Manuscript submission date: 2022-10-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-18 03:52

Reviewer performed review: 2022-10-26 10:30

**Review time:** 8 Days and 6 Hours

Scientific quality	[Y] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[ ]Yes [Y]No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous
statements	Conflicts-of-Interest: [Y] Yes [] No

## SPECIFIC COMMENTS TO AUTHORS

For my opinion, it's more practical to expand the supply channels of drugs and consider similar low-cost drugs in resource limited settings.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

# PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 80829

Title: Access to novel anti-diabetic agents in resource limited settings- a brief

commentary

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05347361 Position: Peer Reviewer Academic degree: MD

**Professional title:** Associate Professor, Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: South Africa

Manuscript submission date: 2022-10-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-16 14:51

Reviewer performed review: 2022-11-22 13:24

**Review time:** 5 Days and 22 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes []No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

The authors discussed the access to novel antidiabetic agents in resource limited settings, considered clinicians were best equipped to lead the process of ensure equity of access. However, I think authors need to consider the local health care policy and economic situation, and if the economic situation is not particularly good, it may be more necessary to invest funds in urgent related treatment.